Figure 8. Survival after increasing doses of flavopiridol, selective CDK1/2 inhibitor III and specific CDK 4/6 inhibitor was determined in HPV-negative SCC35 and SCC61 (labeled in black) and HPV+ UMSCC47 and SCC090 (labeled in grey) head and neck cancer cell lines; standard deviations are calculated from three independent experiments.
